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Solving the Calciﬁcation Dilemma of Coronary CT Angiography*Matthew J. Budoff, MD,y James K. Min, MDzxSEE PAGE 1045S ince its emergence in 2005, coronary computedtomography angiography (CTA) has maturedinto a robust method for direct visualization
of the coronary arteries and atherosclerotic plaque.
Early prospective multicenter studies reported high
diagnostic performance for coronary CTA in the iden-
tiﬁcation and exclusion of high-grade coronary steno-
ses compared with the reference standard of invasive
coronary angiography (ICA) (1–3). Both direct and his-
torical comparison data have established the superi-
ority of coronary CTA over functional stress testing
for identiﬁcation of anatomically obstructive coro-
nary artery disease.
Despite diagnostic sensitivities of coronary CTA
that approached 100% for coronary artery disease,
speciﬁcities were markedly lower, ranging between
64% and 90% for coronary CTA–determined stenosis
severity and reﬂecting a non-negligible rate of false-
positive ﬁndings wherein coronary CTA diagnoses
overestimate the severity of the luminal narrowing.
This reduced performance has been attributed to
limitations mainly caused by motion and calcium ar-
tifacts; the former has largely been overcome with the
use of pre-procedural beta-blockers and higher tem-
poral resolution CT scanners.*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC:
Cardiovascular Imaging or the American College of Cardiology.
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partial volume effects, has remained problematic.
The magnitude of the adverse diagnostic effects of
coronary calciﬁcation on coronary CTA was high-
lighted in a recent meta-analysis of 1,634 patients
from 19 studies that examined the performance of
coronary CTA across different thresholds of coronary
artery calcium (CAC) scores (4). Subgroups at CAC
scores <10 and <100 demonstrated high speciﬁcities
of 90% (94% to 100%) and 88.5% (81% to 91.5%),
respectively, whereas at CAC scores >400, the spec-
iﬁcity declined signiﬁcantly to 42% (28% to 56%)
while retaining a high sensitivity of 97.5% (94% to
99%). These may, in part, explain the equally con-
cerning ﬁndings that among stenoses considered
high-grade according to coronary CTA, nearly 75% are
not ischemia-causing compared with invasive frac-
tional ﬂow reserve (FFR).The study by Nørgaard et al. (5) in this issue
of iJACC represents ﬁndings from the prospective,
international, multicenter NXT (Analysis of Coronary
Blood Flow Using CT Angiography: Next Steps) trial,
which evaluated the diagnostic performance of frac-
tional ﬂow reserve derived from coronary computed
tomography angiography (FFRCT), a novel method
approved by the US Food and Drug Administration
that uses computational ﬂuid dynamics applied
to typical coronary CTA images for calculation of
FFR (6). Importantly, FFRCT enables calculation
of “3-vessel” FFR because it can interrogate any
point within the coronary vascular bed for its
hemodynamic signiﬁcance. In NXT, the primary
endpoint was 1 of discrimination (i.e., the area under
the receiver-operating characteristic curve [AUC])
because this metric allows identiﬁcation of the
optimal sensitivity and speciﬁcity for any given test.
On a per-patient basis, the AUC was 0.90 for FFRCT,
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ischemia-causing coronary lesions by FFR. These data
evoked optimism for a technique that allows for
direct visualization of coronary artery anatomy
(by coronary CTA) and precise identiﬁcation of the
coronary artery stenoses that cause ischemia (by
FFRCT). Notably, the average CAC score in NXT was
302 Agatston units, which places the study popula-
tion in the prognostically worst risk category when
deﬁned according to the Multi-Ethnic Study of
Atherosclerosis (7).
However, the detailed breakdown of FFRCT accu-
racies across coronary calcium score ranges was not
detailed in the original NXT paper (6) and is the
subject of the paper by Nørgaard et al. (5). For 214
patients who underwent CAC scoring in NXT, with
333 vessels directly examined by using FFR, the
diagnostic performance of FFRCT was evaluated for
study-speciﬁc quartiles of CAC scoring. Interestingly,
the investigators observed no differences in diag-
nostic accuracy, sensitivity, or speciﬁcity of FFRCT
across any CAC score quartiles, including no differ-
ences at even the highest quartile of patients with
Agatston CAC scores ranging from 416 to 3,599. For
these patients, FFRCT showed marked improved
discrimination of ischemia compared with coronary
CTA alone (AUC: 0.91 vs. 0.71; p ¼ 0.0004). Indeed, in
this highest quartile, FFRCT reclassiﬁed 60% of cases,
leading to a signiﬁcant reduction in false-positive
ﬁndings. These results emphasize the immunity of
FFRCT to the largest imaging limitation of coronary
CTA and demonstrate that the test is not affected by
even the most severe calciﬁcations.
Before the introduction of FFRCT, there was no
noninvasive method for simultaneous detection of
coronary stenosis and determination of whether that
stenosis causes ischemia. This ability to precisely
locate a lesion that may beneﬁt from coronary
revascularization represents a signiﬁcant advance-
ment in diagnostic imaging. Added to the visualiza-
tion of atherosclerotic plaque features that augment
the diagnosis of coronary lesion–speciﬁc ischemia,
the use of FFRCT may enable pre-procedural planning
in a manner that other modalities do not. In addition,
its general immunity to coronary calciﬁcation repre-
sents a major advance compared with coronary CTA
imaging.
These data (5), although from a substudy of a larger
parent trial, are of considerable import in today’s
health caremilieu, in which false-positive noninvasive
imaging test results commonly beget unnecessary ICA
for subjects who are subsequently found not to have
disease. In a recent report from the National Cardio-
vascular Data Registry of 661,063 patients undergoingelective ICA after functional stress testing, more than
one-half of patients did not have any actionable coro-
nary stenosis, with the majority of patients having
normal coronary arteries, conﬁrming the low diag-
nostic accuracy of stress testing that is observed in
current clinical practice (8). Among the 302,651 pa-
tients who underwent myocardial perfusion imaging
(the most commonly used test in the United States
today), only 134,670 (44.4%) had obstructive disease
at ICA. Exercise treadmill testing, stress echocardiog-
raphy, and magnetic resonance imaging yielded simi-
larly low rates of obstructive disease. These ﬁndings
are in direct accordance with a recent 47-center study
of the Advanced Cardiovascular Imaging Consortium
by Chinnaiyan et al. (9), in which stress test results did
not predict the presence of anatomically obstructive
coronary artery disease at ICA.
Numerous other clinical and economic assessment
studies for FFRCT are ongoing. In the recently re-
ported RIPCORD (Does Routine Pressure Wire
Assessment Inﬂuence Management Strategy at Coro-
nary Angiography for Diagnosis of Chest Pain) study,
which was presented in abstract form at the 2015
EuroPCR Scientiﬁc Sessions, FFRCT was evaluated for
its ability to inﬂuence clinical decision making in
salutary fashion (10). In 200 consecutive patients in
stable condition with chest pain, cardiologists’ deci-
sion making was tested when using standard coro-
nary CTA versus coronary CTA plus FFRCT. In this
study by Curzen et al., 12% of patients who would
have been treated with medical therapy alone would
have been sent for ICA with intended revasculariza-
tion if the FFRCT results were known. Conversely,
30% of patients who would have been referred to ICA
were reassigned to medical therapy alone when using
FFRCT added to coronary CTA. Nearly 20% of patients
who were chosen for coronary revascularization were
found to have different vessels needed for treatment,
a ﬁnding highlighting the ability of FFRCT to perform
3-vessel evaluation.
Two additional ongoing FFRCT trials are notable.
The multicenter PLATFORM (Prospective Longitu-
dinal Trial of FFRCT: Outcome and Resource Impacts
[NCT01943903]) trial of nearly 600 patients (whose
enrollment is completed; results are expected to be
reported in 2015) is a 2-period prospective evaluation
of current practice versus FFRCT-based practice. It has
a 90-day primary endpoint of ICA normalcy; second-
ary endpoints will include major adverse cardiac
events, quality of life, medical radiation, and
resource consumption. Finally, the multinational
CREDENCE (Computed Tomographic Evaluation of
Atherosclerotic Determinants of Myocardial Ischemia
[NCT02173275]) trial of >600 patients is comparing
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1058coronary CTA and FFRCT head-to-head against stress
testing for deﬁnitive determination of which methods
are best for the diagnosis of ischemia. These trials will
further inform the clinical cardiovascular imaging
community on the use of FFRCT. At present, however,
the technology seems to have taken 1 large step closer
to a “1-stop shop” of anatomic identiﬁcation ofcoronary stenoses as well as determination of their
physiologic signiﬁcance.
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